Entering text into the input field will update the search result below

Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q2 2018 Results - Earnings Call Transcript

Aug. 04, 2018 9:42 AM ETIntra-Cellular Therapies, Inc. (ITCI)
SA Transcripts profile picture
SA Transcripts

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2018 Earnings Conference Call August 2, 2018 8:30 AM ET


Juan Sanchez – Vice President of Investor Relations

Sharon Mates – Chairman and Chief Executive Officer

Larry Hineline – Vice President and Chief Financial Officer

Andrew Satlin – Executive Vice President and Chief Medical Officer


Brian Abrahams – RBC Capital Markets

Sumant Kulkarni – Canaccord

Robert Hazlett – BTIG

Matt Kaplan – Ladenburg Thalmann

Jason Butler – JMP Securities


Good morning, ladies and gentlemen and welcome to the Intra-Cellular Therapies Second Quarter 2018 earnings conference call. [Operator Instructions].

I would now like to turn the conference over to your host Dr. Juan Sanchez, Vice President of Investor Relations and Corporate Communications. You may begin.

Juan Sanchez

Thank you, operator. Good morning and thank you all for joining us for today’s conference call.

Our earnings press release providing a corporate update and details of the company’s financial resources for the second quarter ended June 30, 2018 crossed the wire a short time ago and it’s available on our website at intracellulartherapies.com.

Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer; Dr. Kimberly Vanover, Senior Vice President of Clinical Development; Larry Hineline, Vice President and Chief Financial Officer; and Michael Halstead, Senior Vice President and General Counsel.

As a reminder, during today’s call we will be making certain forward-looking statement. These statements may include statements regarding among other things, the efficacy, safety and intended utilization of the company’s product development candidates, our clinical or non-critical plans, our plans to present or report additional data, the anticipated conduct and results of future clinical trials, plans regarding regulatory filings, future research and development, and possible uses of existing cash, and investment resources.

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.